Azmi Nabulsi
2021
In 2021, Azmi Nabulsi earned a total compensation of $4.3M as Chief Operating Officer at Phathom Pharmaceuticals, a 83% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $285,846 |
|---|---|
| Option Awards | $3,529,515 |
| Salary | $491,250 |
| Other | $14,625 |
| Total | $4,321,236 |
Nabulsi received $3.5M in option awards, accounting for 82% of the total pay in 2021.
Nabulsi also received $285.8K in non-equity incentive plan, $491.3K in salary and $14.6K in other compensation.
Rankings
In 2021, Azmi Nabulsi's compensation ranked 3,071st out of 12,406 executives tracked by ExecPay. In other words, Nabulsi earned more than 75.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 3,071 out of 12,406 | 75th |
Division Manufacturing | 1,227 out of 5,492 | 78th |
Major group Chemicals And Allied Products | 490 out of 2,368 | 79th |
Industry group Drugs | 433 out of 2,089 | 79th |
Industry Pharmaceutical Preparations | 295 out of 1,536 | 81st |
Source: SEC filing on April 13, 2023.
Nabulsi's colleagues
We found one more compensation record of an executive who worked with Azmi Nabulsi at Phathom Pharmaceuticals in 2021.
2021
Terrie Curran
Phathom Pharmaceuticals
Chief Executive Officer
News
Phathom Pharmaceuticals CEO Terrie Curran's 2023 pay falls 32% to $3.4M
April 12, 2024
Phathom Pharmaceuticals CEO Terrie Curran's 2022 pay slips 20% to $5M
April 13, 2023
Phathom Pharmaceuticals CEO Terrie Curran's 2020 pay jumps 34% to $4.6M
April 6, 2021
Phathom Pharmaceuticals CEO Terrie Curran receives $3.5M in 2019
April 8, 2020